
News & Events category:
Manchester Royal Infirmary
News about Manchester Royal Infirmary


MFT recruits final participant to Phase 3 COVID-19 vaccine study
Manchester University NHS Foundation Trust (MFT), England’s largest NHS trust, has recruited its final participant to a leading COVID-19 vaccine trial.
Read more
MFT researcher and doctor contributes to national guidance for patients managing high cholesterol during the COVID-19 pandemic
A Manchester Royal Infirmary doctor and researcher has coordinated a national team of experts to publish guidance for clinicians to help them safely manage hyperlipidaemia patients during the pandemic
Read more
YNM2020: A year as a ‘highly commended’ member of Research and Innovation staff – a blog by Sindhu John, Nurse Manager
In January, Sindhu John was named as one of the highly commended members of Research and Innovation staff for 2020: Year of the Nurse and Midwife. She reflects on her year in this blog.
Read more
YNM2020: A year as a Research and Innovation ‘highly commended’ member of staff – a blog by Womba Mubita, Research Nurse Manager
In January, Womba Mubita was named as one of the highly commended members of Research and Innovation staff for 2020: Year of the Nurse and Midwife. She reflects on her year in this blog.
Read more
YNM2020: A year as the Research and Innovation Nurse of the Year – a blog by Vicki Conroy, Research Nurse Manager
In January, Vicki Conroy was named as the MFT YNM2020 Nurse of the Year for Research and Innovation. She shares her pride in both the award and her team, and reflects on her experiences, in this blog
Read more
Manchester-designed Arterial Sheath could improve surgical outcomes for patients with complex aortic aneurysms
A 3D-printed medical device made in Manchester could help improve surgical outcomes for patients with abdominal aortic aneurysm (AAA) – a potentially life-threatening condition in the body’s main bloo
Read more
MFT Research finds cellular immunity to virus that causes COVID-19
Cellular (T-cell) immunity against SARS-CoV-2 is likely to be present within most adults for at least six months after infection, according to research carried out at MFT.
Read more